Urologic Oncology Articles

Rocapuldencel-T Falls Short in mRCC
An interim analysis revealed that the immunotherapy rocapuldencel-T is unlikely to meet any of the primary endpoints of the phase III ADAPT trial in patients with metastatic renal cell carcinoma. 
Anti-PD-1 Biomarker Analysis Shows Promise for MDSCs, IFN-Gamma
A search for molecular guidance in the use of anti-PD-1 therapy in urothelial cancer pointed toward myeloid-derived suppressor cells as a potentially useful biomarker.
FDA Approves Nivolumab/Ipilimumab for Frontline RCC
The FDA has approved the combination of nivolumab and ipilimumab as a frontline treatment for intermediate- and poor-risk patients with advanced renal cell carcinoma.
Treatment Developments Shaking Up Landscape for Nonmetastatic CRPC
Mark J. Mann, MD, discusses the developing treatment landscape for patients with nonmetastatic CRPC.
Adjuvant Axitinib Falls Short in Phase III RCC Trial
Adjuvant axitinib did not extend disease-free survival versus placebo for patients at high risk of recurrent renal cell carcinoma after nephrectomy, according to findings from the phase III ATLAS trial.
 
POUT Data Show Benefit of Adjuvant Chemotherapy in Patients With UTUC
Data from the phase III POUT clinical trial demonstrated that adjuvant platinum-based chemotherapy improves disease-free survival and metastasis-free survival in patients with upper tract urothelial carcinoma.
Surgical Challenges Remain Among Recent Successes in Kidney Cancer
Hyung L. Kim, MD, discusses perioperative systemic therapy for patients with kidney cancer.
Standardization, Simplification Needed for Wider Adoption of Robotic Cystectomy
Amit Gupta, MD, discusses the superiority of robotic cystectomy compared with open cystectomies and its relevance in the current treatment landscape of bladder cancer.
Multimodal Approaches Emerging in Locally Advanced Prostate Cancer
Edouard J. Trabulsi, MD, discusses emerging multimodal treatment approaches for patients with locally advanced prostate cancer.
Prostate Cancer Screening and Surveillance Continue to Evolve
William K. Kelly, DO, discusses the evolving imaging techniques and emerging therapeutic approaches in prostate cancer.
Publication Bottom Border
Border Publication
x